Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLingshuang ShengShanghai Jiao Tong UniversityRSRong ShenAnhui University of Traditional Chinese MedicineZYZi‐Xun YanShanghai Jiao Tong University

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows TP53 mutation does not significantly alter safety or progression-free survival in LBCL patients receiving CD19-CAR-T therapy.

Key Points

  • This research focuses on the effect of TP53 mutation on treatment outcomes in patients with large B-cell lymphoma receiving CD19-CAR-T therapy.
  • Retrospective analysis of R/R LBCL patients treated with CD19-CAR-T therapy.
  • Utilized next-generation sequencing to detect genomic mutations.
  • Outcomes measured included progression-free survival, overall survival, and safety of the therapy.
  • The TP53 mutation did not significantly impact progression-free survival and overall survival in the overall population.
  • Patients with TP53-mutated LBCL showed comparable safety profiles with those who were TP53-wild type.
  • Median progression-free survival was markedly poorer for TP53-mutated patients receiving 4-1BB CAR-T products.

Cite This Study

Sheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e44dhttps://doi.org/10.1182/blood-2025-1746
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma2025 · 1 citations
  2. 2Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma2025
  3. 3Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.2025 · 2 citations
  4. 4Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy2026
  5. 5CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier2025